Rocheheraldedthelate-stagesuccessoftwobigtrialsforitsmultiplesclerosisdrugocrelizumabtoday,whichtheysayputsthemonastraightroadtoregulatoryfilingsfortheIVantibodydruginearly.Butevenunderthebest-casescenarioforthefuture,theBigPharmaplayerwillfaceatoughtasksquaringoffagainsttheneworaldrugsthathavebeendivvyingupthisbigmarketrecently.
Rocheisholdingbackthedatafornow,butthepharmagiantsaysthattheirdrugbeatoutRebifonbothprimaryandsecondaryendpointsintheirOperaIandOperaIIstudies.Investigatorssaythedrugwasbetteratreducingtherateofannualizedrelapsesovertwoyearswhileslowingtheprogressionofclinicaldisability(essentially,thedeclinepatientsexperienceovertime).Andtherewerealsofewerlesionsfoundinthebrainsofpatientstakingthenewdrug.
Roche--whichhasoneofthebiggestRDbudgetsinthebusiness--neededthePhaseIIIwin.AnalystshavebeguntogrowrestiveovertheapparentlackofprogressthatthepharmagianthasshownintheclinicrecentlyandRocheCEOSeverinSchwanhastoutedocrelizumabslikelyprogressthisyearascauseforhopeinseeingimportantnewproducts白癜风的治愈中医治疗白癜风方法
转载请注明：http://www.ebsaw.com/jbyf/2220.html
